Theriva Biologics (NYSE American: TOVX) details new 2026 investor deck

Rhea-AI Filing Summary

Theriva Biologics, Inc.

The presentation includes forward-looking statements language under the Private Securities Litigation Reform Act of 1995, indicating that it discusses expectations and plans in addition to historical information. No new financial results or major transactions are described in this report itself; it primarily alerts investors to the availability of the updated presentation.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

01/12/2026 - 09:11 AM

false 0000894158 0000894158 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

THERIVA BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-12584		13-3808303
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

(301) 417-4364

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨		Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
¨		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	TOVX	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

Theriva Biologics, Inc. (the “Company”) will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the Company updated presentation, which is filed as Exhibit 99.1 to this Current Report on Form 8-K.

The Company’s presentation filed as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

Item 9.01. Financial Statements and Exhibits.

(d)   Exhibits.

Exhibit Number		Description
99.1		Presentation of Theriva Biologics, Inc., dated January 2026
104		Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 12, 2026	THERIVA BIOLOGICS, INC.
	By:	/s/ Steven A. Shallcross
		Name:	Steven A. Shallcross
		Title:	Chief Executive Officer and Chief Financial Officer

FAQ

What did Theriva Biologics (TOVX) disclose in this 8-K?

Theriva Biologics disclosed that it will be making several investor presentations over the next several weeks and that it has filed an updated investor presentation as Exhibit 99.1, dated January 2026.

What is included in Theriva Biologics' Exhibit 99.1 investor presentation?

Exhibit 99.1 is an updated investor presentation for Theriva Biologics, dated January 2026, which the company plans to use in upcoming meetings with investors.

Does this Theriva Biologics (TOVX) filing contain new financial results?

The filing does not describe new financial results; it primarily notes that an updated investor presentation has been filed and will be used in investor meetings.

Why does Theriva Biologics' investor presentation include safe harbor language?

The presentation includes safe harbor language under the Private Securities Litigation Reform Act of 1995 because it contains forward-looking statements in addition to historical information.

Where can investors find the updated Theriva Biologics (TOVX) presentation?

Investors can find the updated presentation as Exhibit 99.1 to this report, described as the Presentation of Theriva Biologics, Inc., dated January 2026.

Who signed this Theriva Biologics (TOVX) report?

The report was signed on behalf of Theriva Biologics, Inc. by Steven A. Shallcross, the company’s Chief Executive Officer and Chief Financial Officer.